Abstract
It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.
Keywords: Prostate Cancer, Androgen Biosynthesis, Cytochrome P450 enzyme 17R-hydroxylase-17, 20-lyase, Virtual Screening
Letters in Drug Design & Discovery
Title: Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design
Volume: 6 Issue: 5
Author(s): Pelin Armutlu, Muhuttin Emre Ozdemir, Sule Ozdas, Ibrahim Halil Kavakli and Metin Turkay
Affiliation:
Keywords: Prostate Cancer, Androgen Biosynthesis, Cytochrome P450 enzyme 17R-hydroxylase-17, 20-lyase, Virtual Screening
Abstract: It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.
Export Options
About this article
Cite this article as:
Armutlu Pelin, Ozdemir Emre Muhuttin, Ozdas Sule, Kavakli Halil Ibrahim and Turkay Metin, Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design, Letters in Drug Design & Discovery 2009; 6 (5) . https://dx.doi.org/10.2174/1570180810906050337
DOI https://dx.doi.org/10.2174/1570180810906050337 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer
Current Pharmaceutical Design Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design SUBJECT INDEX TO VOLUME 1
Current Drug Safety Smell and Taste Disorders Resulting from Cancer and Chemotherapy
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of Thiohydantoin Derivatives as Novel Anti-prostate Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Monoterpenoid Plant-Plant Interactions Upon Herbivory
Current Bioactive Compounds Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry Anti-cancer Scopes and Associated Mechanisms of Scutellaria Extract and Flavonoid Wogonin
Current Cancer Therapy Reviews Immunomodulatory Properties of Thalidomide Analogs: Pomalidomide and Lenalidomide, Experimental and Therapeutic Applications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Graphical Abstracts:
Current Cancer Drug Targets miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status
Current Molecular Medicine